Monte Rosa Therapeutics : Corporate Presentation – May 2026

Published: 2026-05-07 07:35:00 ET GLUE

Published on 05/07/2026 at 07:35 am EDT

Degrading Proteins, Making Medicines

Innovating Beyond New Heights | May 2026

Additional INDs for wholly owned pipeline anticipated over next 2 years

Uniquely differentiated "only in class"

pipeline with 3 clinical programs

Addressing highly validated,

undruggable targets

in high medical need indications

Three programs initiating Phase 2 trials in 2026

Building the Future

Potential multi-billion-dollar market opportunities with only-in-class MGDs

Leaders in AI-driven protein-protein interaction (PPI) prediction and rational design of novel MGDs

Industry-leading product engine with a focus on molecular glue degraders (MGDs) with unprecedented selectivity

Positioned for Execution

~$350M in collaboration payments in last 3 years with potential for >$400M over the next 24 months

Funded through multiple anticipated Phase 2 studies of MRT-6160,

MRT-8102, and MRT-2359

Strong balance sheet providing cash runway into 2029

Monte Rosa Therapeutics - A Leader in Targeted Protein Degradation

Next-Gen MGD-Based Therapeutics Delivering Meaningful Clinical Results

First-in-class VAV1 MGD MRT-6160

for diverse T and B-cell driven diseases

First-in-class NEK7 MGD MRT-8102

for NLRP3/IL-1/IL-6 driven diseases

Best-in-class GSPT1 MGD MRT-2359

for AR mutant metastatic CRPC

GSPT1

Biomarker Level

(% Change from Predose at 24h)

-20

-40

-60

-80

-100

IL-2 IL-17A IFN-γ

Median hsCRP (%Change From Predose)

-20

-40

-60

-80

-100

Placebo

MRT-8102

1 2 3 4

Time Post Randomization (Weeks)

Best % change in PSA

-20

-40

-60

-80

-100

Monte Rosa Pipeline and Upcoming Milestones

Target

Immunology & Inflammation

VAV1

Licensed to Novartis*

NEK7

Compound

MRT-6160

MRT-8102

Phase 2 initiation

in Q3 2026

Next Generation

Indication(s)

Immune-mediated Diseases

IL-1β/NLRP3-driven Inflammatory Diseases

Preclinical

Phase 1 Phase 2

Phase 3

Next Anticipated Milestone

Multiple Phase 2

initiations in 2026

Phase 1 data and Phase 2 initiation in H2 2026

IND submission for CCNE1 MGD in H2 2026

IND submission in H2 2026

Oncology

GSPT1

MRT-2359

Castration-resistant Prostate Cancer

CCNE1/ CDK2

Discovery

CCNE1 Amplified Tumors ER+ Breast Cancer

Various

Multiple Targets

Includes those licensed/optioned to Roche and Novartis

Discovery

I&I, Oncology, Genetic and Neurological Diseases

Announce additional targets

* Novartis has exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs. Monte Rosa is eligible for up to $2.1B in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies, and is also eligible for 30% US P&L share and ex-US tiered royalties.

Notes: IND = investigational new drug. ER = estrogen receptor. I&I = immunology and inflammation.

Monte Rosa MGDs: Opportunity for Paradigm-Changing Medicines

Most disease-causing proteins are

Clinically validated modality

Exquisite selectivity

Novel target space

Catalytic mechanism of action

Oral dosing

Scalable manufacturing

6 Like RNAi and CRISPR, Monte Rosa's MGDs have the potential to unlock undruggable target space

but with the advantages of oral small molecules

QuEEN Product Engine Delivering Differentiated Drug Candidates

Expansive and expanding novel target space

Rational MGD design

Exquisitely selective target silencing

QuEEN featured in Science July 2025

Highly potent degraders with drug-like properties, oral bioavailability, and systemic distribution to all target tissues

Deep understanding of PK/PD for clinical translation

Convenient, highly effective, orally available alternative to injectable biologics

Creating Value through Strategic Collaborations

Scope

Financials

Strategic Goal

Global license agreement to advance VAV1-directed molecular glue degraders including MRT-6160 (announced Oct. 2024)

$150M upfront payment

Eligible for up to $2.1B in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies

NVS fully funds Phase 2 studies

Eligible for 30% US P&L share

and ex-US tiered royalties

Accelerate and broaden scope of clinical development of MRT-6160 while retaining substantial value for Monte Rosa

Collaboration with Novartis for degraders to treat immune-mediated diseases (announced Sep. 2025)

$120M upfront payment plus option maintenance payments

Eligible for option exercise payments and development, regulatory, and sales milestones, as well as tiered royalties on global net sales

Up to $5.7B total deal value

Expedite additional I&I programs leveraging Monte Rosa QuEEN platform and Novartis capabilities in immune-mediated diseases

Strategic collaboration to discover novel MGDs targeting cancer and neurological diseases (announced Oct. 2023)

$50M upfront payment

Eligible for >$2B preclinical, clinical, commercial and sales milestone payments and tiered royalties

Expand platform reach to discover and develop MGDs against previously undruggable targets in cancer and neurological diseases

Notes: Under the terms of the Oct. 2024 Novartis agreement, Novartis has exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs and is responsible for all clinical development and commercialization, starting with Phase 2 clinical studies. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S. Under the terms of the Sep. 2025 Novartis agreement, Monte Rosa granted Novartis an exclusive license to an undisclosed target and the exclusive option to obtain licenses to two programs from Monte Rosa's preclinical immunology portfolio. Under the terms of the Roche agreement, Monte Rosa Therapeutics will lead discovery and preclinical activities against multiple select cancer and neurological disease targets to a defined point. Roche gains the right to exclusively pursue further preclinical and clinical development of the compounds.

I&I Pipeline

Beyond Biologics-in-a-Pill: Potential for Next-Generation I&I Drugs

Degrading previously undruggable signaling nodes to modulate multiple cytokines

MRT-6160 (VAV1) stops multiple pathogenic cytokines (IL-2, IL-6, IL-17) and secreted antibodies (sIgG)

MRT-8102 (NEK7) stops multiple pathogenic cytokines (IL-1α/β, IL-18, IL-6) and pyroptosis

TCR

IL-2 IL-17 IFN-γ

VAV1

BCR

IL-6

sIgG

VAV1

B-cell

Transcriptional activation

N-γ

Transcriptional activation

NLRP3 activating stimuli

(e.g., cholesterol, MSU crystals, FFAs, fibrils, PAMPs)

IL-1β IL-18

IL-1α

DAMPS

Pyroptosis

NLRP3

inflammasome

NEK7

Pyroptotic release

IL-6

sIgG

Acute-phase response

Paracrine amplification

IL-6 induction via IL-1

IL-6 TNF-α

IL-2

T-cell

hsCRP

SAA

Fibrinogen

Expanding High-Value I&I Pipeline with Oral Degraders

Multiple undisclosed targets in Th1, Th2, Th17, and myeloid pathways and B-cell modulation

DNA sensing

NK cell

Monocyte

Apoptotic cell

Myeloid

pDC

Neutrophil

Cell-driven

nflammation

Neutrophil

ADAPTIVE

INNATE Type I IFN

mDC

B-cell

Modulation

Complement

Autoantibodies

T cell

B cell

Pro-inflammatory cytokines

(e.g., BAFF & TNF)

Type 2 Inflammation

Th1 / Th17 Autoimmunity

VAV1 Program (MRT-6160)

VAV1: Upstream Targeting Node Associated with Clinically Validated Pathways

VAV1 signaling is associated with several T and B cell immunologic outcomes

Clinically validated pathway in autoimmune/inflammatory disease

VAV1

T cell activation

B cell activation/Plasma cell differentiation

(Antibody production)

Th17 response

Pro-inflammatory cytokine production

VAV1: Unique Mechanism with Broad Potential Applications

Potential to address multiple autoimmune diseases with safe, oral therapy

T-cell mediated T/B-cell mediated

Evidence of VAV1 mechanistic overlap

TNF

IL6

Example Drugs

2030E Drug Class Sales (I&I indications only)

Humira, Enbrel

Taltz, Cosentyx

$9B

Actemra, Kevzara

$3B

$16B

FcRN

Vyvgart

$14B

CD20

Ocrevus, Rituxan

$14B

JAK

Rinvoq, Xeljanz, Olumiant

$14B

TYK2

Sotyktu

$3B

VAV1

Overlap

✓

✓ ✓

Approved in indication Investigational

Note: Chart adapted from Hosack et al., Nat Rev Rheumatol 2023. Drug class sales from Evaluate Pharma. 2030E sales may include sales from anticipated future approvals.

MRT-6160 Blocked T-cell-mediated B-cell Activity in BioMAP® Profile

T-cell independent

BT coculture assay:

T-cell-mediated B-cell activity

Azathioprine

Relative protein expression levels

JAKi

TYK2i

BTKi

VAV1 MGD

Decreased T / B-Effector Function:

15 IL-17A, IL-17F, IL-6, IL-2, TNF, sIgG

Azathioprine, 100 μM

Upadacitinib, 1000 nM

Deucravacitinib, 400 nM

Ibrutinib, 1100 nM

MRT-6160, 1000 nM

BioMAP® Diversity Plus Platform (Eurofins). Shark tooth plots show relative expression levels of indicated proteins in Drug treated vs. DMSO controls. 3C/4H, Venular endothelial cells; LPS/SAg, Venular endothelial cells + PBMC; BT, PBMC + B cells; BF4T, Bronchial epithelial cells + dermal fibroblasts; BE3C. Bronchial epithelial cells; CASM3C, Coronary artery smooth muscle cells; HDF5CGF, Dermal fibroblasts; KF3CT, keratinocytes + dermal fibroblasts; MyoF, lung fibroblasts; IMphg, macrophages + venular epithelial cells

Preclinical Data Support Broad Potential Applications of MRT-6160

T-cell transfer-induced colitis model

of inflammatory bowel disease

MRL-Faslpr spontaneous autoimmune disease model

(e.g., SLE, Sjögren's)

CD45RBlow non-pathogenic control Vehicle

Upadacitinib, 10 mg/kg

Etrasimod, 3 mg/kg

MRT-6160, 1 mg/kg

Treatment start:

Day 17

DAI Score

(mean ± SEM)

0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45

Time post T cell transfer (Day)

Vehicle

Anti-CD40L, 5 mg/kg

MRT-6160, 1 mg/kg

Treatment start:

Week 11

Lymphadenopathy score

(Max: 6)

9 10 11 12 13 14 15 16 17 18

Age (weeks)

Collagen-induced arthritis model of autoimmune arthritis

EAE model of neuroinflammatory disease (e.g., multiple sclerosis)

Vehicle

Anti-TNF, 10 mg/kg

MRT-6160, 1 mg/kg

Day 0: Disease onset and treatment initiation

Clinical Score

(mean ± SEM)

-6 -3 0 3 6 9 12 15 18 21

Time Post Treatment Initiation (Day)

Vehicle

Fingolimod, 3 mg/kg

MRT-6160, 1 mg/kg

Treatment start:

Day 9

Clinical score

(mean ± SEM)

0 3 6 9 12 15 18

Time post disease induction (Day)

Sources: DDW 2024 poster_T-cell transfer colitis ACR 2025 poster_MRL-FASlpr

EAE = experimental autoimmune encephalomyelitis; SLE = systemic lupus erythematosus

EULAR 2024 poster_CIA

FOCIS_2025 poster_EAE model

MRT-6160 Reduces Pro-Inflammatory Cytokine and Auto-Antibody Levels in Multiple T- and/or T/B-cell Mediated Autoimmune Disease Models

MRT-6160 attenuates pro-inflammatory cytokines

MRT-6160 attenuates autoantibody production

Serum cytokines

(CIA model of autoimmune arthritis)

Serum anti-dsDNA autoantibodies

(MRL-Faslpr spontaneous autoimmune disease model)

10000

IFNɣ (fg/mg)

8000

6000

4000

2000

✱✱

2000

IL-6 (fg/mg)

1500

1000

500

✱✱✱

✱✱

✱✱✱✱

TNF (pg/mL)

✱✱✱

IL-17A (pg/mL)

ns ns

✱

Treatment start:

Week 11

Anti-dsDNA autoantibodies (units/mL)

4×106

3×106

2×106

1×106

0 0 0

9 10 11 12 13 14 15 16 17 18

Week

Sources:

DDW 2024 poster_T-cell transfer colitis ACR 2025 poster_MRL-FASlpr

EULAR 2024 poster_CIA

Strategic Agreement to Accelerate and Broaden MRT-6160 Development

Global license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160, in development for immune-mediated conditions (announced Oct. 2024)

$150M upfront payment

Eligible for up to $2.1B in development, regulatory, and sales milestones, beginning upon initiation of Phase 2 studies

NVS fully funds Phase 2 studies

Eligible for 30% US P&L share and ex-US tiered royalties

Notes: Under the terms of the Novartis agreement, Novartis has exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1 MGDs and is responsible for all clinical development and commercialization, starting with Phase 2 clinical studies. Monte Rosa remains responsible for completion of the ongoing Phase 1 clinical study of MRT-6160. Monte Rosa will co-fund any Phase 3 clinical development and will share any profits and losses associated with the manufacturing and commercialization of MRT-6160 in the U.S.

Safety, PK and PD Data from SAD and MAD Healthy Volunteers Phase 1 Trial of VAV1 MGD MRT-6160

MRT-6160 Phase 1 Healthy Volunteers Study: Design and Objectives

All cohorts randomized & placebo controlled

One oral dose 7 daily oral doses

SAD DL5

SAD DL4

SAD DL3

MAD DL3

SAD DL2

MAD DL2

SAD DL1

MAD DL1

Safety and tolerability

Pharmacokinetics

Pharmacodynamics

VAV1 degradation in T & B cells

Ex vivo response to TCR- and BCR-stimulation

Disclaimer

Monte Rosa Therapeutics Inc. published this content on May 07, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2026 at 11:32 UTC.